Whitebox Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Whitebox Advisors’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-400,000	Closed	-$4.19M	–	705
2026 Q1	$4.19M	Hold	400,000	–	–	0.05%	131
2025 Q4	$4.15M	Hold	400,000	–	–	0.06%	143
2025 Q3	$4.11M	Hold	400,000	–	–	0.06%	137
2025 Q2	$4.08M	Hold	400,000	–	–	0.09%	134
2025 Q1	$4.01M	Buy	+400,000	New	+$4M	0.1%	128

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Whitebox Advisors's DMAA Position: Q2 2026 in Review

Whitebox Advisors sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 400,000 shares — an estimated $4.19M sold.

Whitebox Advisors first reported a position in DMAA in Q1 2025 and held it in 5 quarters. The position peaked at $4.19M in Q1 2026. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Whitebox Advisors reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
Whitebox Advisors sold 400,000 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $4.19M.
Whitebox Advisors first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 5 quarters.
Whitebox Advisors's Drugs Made In America Acquisition Corp position peaked at $4.19M in Q1 2026.
18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Whitebox Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.